Inherited metabolic disorders

Metachromatic leukodystrophy (MLD)

Metachromatic leukodystrophy (MLD) is a rare, life-threatening inherited metabolic disorder. MLD is caused by a mutation in the ARSA (arylsulfatase-A) gene, leading to a deficiency in the ARSA enzyme, the accumulation of sulfatides and the progressive destruction of the myelin sheath in nerve cells. As a result, patients experience a progressive deterioration in their neurological and motor function. In the most common form of the disease, late-infantile MLD (~60% of MLD), symptoms are usually observed before the age of 3 years and mortality at 5 years is estimated at 75%. In juvenile MLD (~30% of MLD), symptoms are usually observed between the age of 3 and 16 years, and mortality at 5 years is estimated at 30% in this population (Mahmood 2010). In adult MLD (~10% of MLD), the onset of symptoms usually occurs from the age of 16 years. The incidence of MLD is currently estimated at approximately 1 in 100,000 live births, although it can vary depending on the geographical location (sources: Bonkowski 2010; Poupetova 2010; Lugowska 2011; Kehrer 2011; AL-Jasmi 2012; Stellitano 2016).

Currently, there are no effective treatments for MLD. Allogenic haematopoietic stem cell transplantation has limited efficacy in arresting disease progression and is therefore not considered as a standard of care. Palliative care involves medications for seizures and pain, antibiotics and sedatives, on a case-by-case basis, as well as physiotherapy, hydrotherapy and tube feeding or gastrostomy in the later stages of the disease. The impact of MLD on caregivers and families is considerable.

OTL-200: autologous ex vivo lentiviral gene therapy in clinical development for MLD

Orchard is developing OTL-200, autologous ex vivo lentiviral gene therapy for MLD. Data from the ongoing registrational study have been published in the Lancet in 2016. In this study, early treatment with OTL-200 in most asymptomatic patients has demonstrated preservation of cognitive and motor development to levels comparable with healthy individuals (source: Sessa 2016). The median follow-up period was 3 years (range 18–54 months). These results contrast with outcomes observed in the untreated siblings of the late infantile patients in the clinical study and in aged-matched historical controls, in whom gross motor function typically declines rapidly from the onset of symptoms leading to death in many cases by the age of 5 years. The treatment procedure was well tolerated, and no serious adverse events related to the medicinal product were reported.

OTL-200 was acquired from GSK in April 2018. Orchard is completing an ongoing clinical study with the cryopreserved formulation of OTL-200, while discussions with regulatory authorities continue in anticipation of a submission for a marketing authorization application with regulatory authorities.

For more information please contact: info@orchard-tx.com

 

 

Mucopolysaccharidosis type IIIA (MPS-IIIA)

Mucopolysaccharidosis type IIIA (MPS-IIIA or Sanfilippo syndrome type A) is a rare, life-threatening inherited metabolic disease. MPS-IIIA is the most frequent and severe form of Sanfilippo syndrome. MPS-IIIA is caused by a genetic defect in the SGSH (sulfoglycosamine-sulfohydrolase) gene, which results in a deficiency of SGSH, a crucial enzyme involved in the breakdown of glycosaminoglycans.

As a result, glycosaminoglycans accumulate in cells, tissues, and organs, particularly in the brain. Following 1-2 years of normal development after birth, patients will experience a progressive decline in their neurological function, including speech delay and subsequent loss of language, disturbed sleep, hyperactivity, behavioural disturbance, and impulsivity, as well as difficulty with social interactions. As the disease progresses, patients will display signs of withdrawal. In its most severe form, the disease progresses to severe dementia. The behavioural symptoms generally wane with the onset of severe dementia and the decline of motor function. Life expectancy in MPS-III patients is 10-25 years (source: Lavery 2017). The incidence of MPS-IIIA is currently estimated at approximately 1 in 100,000 live births (source: Valstar 2008).

Currently, treatment options for MPS-IIIA are limited to palliative care only. Allogeneic hematopoietic stem cell transplantation has not been shown to correct or relieve the neurological manifestations of the disease to date.

OTL-201: autologous ex vivo lentiviral gene therapy in preclinical development for MPS-IIIA

Orchard is developing OTL-201, autologous ex vivo lentiviral gene therapy for MPS-IIIA. Data from preclinical studies indicate that treatment with OTL-201 was associated with an increase in SGSH enzyme levels in the brain and in normal behaviour in an open field test (source: Sergijenko 2013). Orchard Therapeutics is currently working with its manufacturing partners and with clinical centres specialized in the treatment of metabolic disorders to initiate clinical studies with OTL-201.

Mucopolysaccharidosis type IIIB (MPS-IIIB)

Mucopolysaccharidosis type IIIB (MPS-IIIB or Sanfilippo syndrome type B) is a rare, life-threatening inherited metabolic disease that is very similar to MPS-IIIA. MPS-IIIB is caused by a genetic defect in the NAGLU (N-alpha-acetylglucosaminidase) gene, which results in a deficiency of NAGLU, a crucial enzyme involved in the breakdown of glycosaminoglycans. As a result, glycosaminoglycans accumulate in cells, tissues, and organs, particularly in the brain.

Following 1-2 years of normal development after birth, patients will experience a progressive decline in their neurological function, including speech delay and subsequent loss of language, disturbed sleep, hyperactivity, behavioural disturbance, and impulsivity, as well as difficulty with social interactions. As the disease progresses, patients will display signs of withdrawal. In its most severe form, the disease progresses to severe dementia. The behavioural symptoms generally wane with the onset of severe dementia and the decline of motor function. Life expectancy in MPS-III patients is 15-30 years (source: Lavery 2017). The overall incidence of MPS-III is currently estimated at approximately 1.5 in 100,000 live births (source: Valstar 2008), and MPS-IIIB represents about one-third of the overall MPS-III population.

Currently, treatment options are limited to palliative care only. Allogeneic hematopoietic stem cell transplantation has not been shown to correct or relieve the neurological manifestations of the disease to date.

OTL-202: autologous ex vivo lentiviral gene therapy in preclinical development for MPS-IIIB

Orchard is developing OTL-202, autologous ex vivo lentiviral gene therapy for MPS-IIIB. Data from preclinical studies indicate that treatment with OTL-202 is associated with an increase in NAGLU enzyme levels in the brain and in normal behaviour in an open field test (source: Holley 2017). Orchard Therapeutics is currently working with its manufacturing partners and with clinical centres specialized in the treatment of metabolic disorders to initiate clinical studies with OTL-202.